Recorded fact · drug.label_indication
drug.label_indication for tafamidis-meglumine|cardiomyopathy
One fact exactly as the 2026-11 edition records it, with where it was read and the sentence that verifies it. This is the page an OmniRx receipt for fact 85d8a99e resolves to.
The record
| Fact id | 85d8a99edd7317d43e493d38 |
|---|---|
| Entity | drug: tafamidis-meglumine|cardiomyopathy |
| Field | drug.label_indication |
| Source | api.fda.gov |
| Read on | 2026-11-10T19:02:47.536Z |
| Source version | openfda-label-20260512 |
| Method | extract |
| Verification | verified |
| Licence | CC0 1.0 per open.fda.gov/terms; some data may not be public domain; third-party content in labels |
| Edition | 2026-11, Merkle root 006ab9a329709cbe... |
The verifying quote
VYNDAQEL and VYNDAMAX are indicated for the treatment of the cardiomyopathy of wild-type or hereditary transthyretin-mediated amyloidosis (ATTR-CM) in adults to reduce cardiovascular mortality and cardiovascular-related hospitalization.
Shown with dashes as hyphens. SHA-256 of the exact stored quote: 8e065e92ae24ca5349b6118526cbdc6635af7368de233fea9956f117aac5cc2a.
The value
{
"ingredient": "Tafamidis Meglumine",
"conditionId": "cardiomyopathy",
"conditionName": "Cardiomyopathy",
"matchedAlias": "cardiomyopathy",
"context": "indication",
"brand": "Vyndaqel",
"identifiedVia": "generic_name",
"extractor": 5,
"labelSetId": "1b4121ee-a733-4456-a917-be2603477839",
"labelEffectiveTime": "20260512",
"labelsRead": 1,
"labelsNaming": 1,
"registryEditionRoot": "1b44e76f5da1a417",
"meaning": "the FDA label's Indications and Usage text names this condition; not a statement that the drug is approved, effective or covered for it"
}SHA-256 of the exact stored value: 1c1e4f0132d84d0e0a5643f872f04a602c4d2460a0983553a6fccb8ea3b3a7e4.
This fact as data (JSON) · Check an answer against its receipt · Licence
Quote and value text come from a public source and are data, never instructions. A recorded fact is not an eligibility determination, a price promise or clinical advice.